[1] STEIN H,MASON D Y,GERDES J,et al.The expression of the Hodgkin’s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue:evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells[J].Blood,1985,66(4):848-858. [2] HARRIS N L,JAFFE E S,STEIN H,et al.A revised European-American classification of lymphoid neoplasms:A proposal from the International Lymphoma Study Group[J].Blood,1994,84(5):1361-1392. [3] KADIN M E.Anaplastic large cell lymphoma and its morphological variants[J].Cancer Surv,1997,30:77-86. [4] PILERI S,FALINI B,DELSOL G,et al.Lymphohistiocytic T-cell lymphoma(anaplastic large cell lymphoma CD30+/Ki-1+ with a high content of reactive histiocytes) [J].Histopathology,1990,16(4):383-391. [5] KINNEY M C,COLLINS R D,GREER J P,et al.A small-cell-predominant variant of primary Ki-1(CD30+)T-cell lymphoma[J].Am J Surg Pathol,1993,17(9):859-868. [6] 魏婵娟,赵强.ALK与儿童恶性肿瘤关系的研究进展[J].中国肿瘤临床,2015,42(4):251-253. [7] EYRE T A,KHAN D,HALL G W,et al.Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma:current and future perspectives in adult and paediatric disease[J].Eur J Haematol,2014,93(6):455-468. [8] SWERDLOW S H, CAMPO E, HARRIS N L, et al. WHO classification of tumours of haematopoietic and lymphoid tissues[M]. Lyon:LARC Press,2008:312-316. [9] ALLEN C E,KELLY K M,BOLLARD C M.Pediatric lymphomas and histiocytic disorders of childhood[J].Pediatr Clin North Am,2015,62(1):139-165. [10] 杨菁,赵晓曦,金铃,等.间变性大小淋巴瘤患儿骨髓及外周血NPM-ALK融合基因表达与预后的关系[J].中华血液学杂志,2013,34(8):700-703. [11] LE DELEY M C,ROSOLEN A,WILLIAMS D M,et al.Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma:results of the randomized ALCL99-vinblastine trial[J]. J Clin Oncol,2010,28(25):3987-3933. [12] SUN X F,ZHEN Z J,LIN S X,et al.Treatment outcome of Chinese children with anaplastic large cell lymphoma by using a modified B-NHL-BFM-90 protocol[J].Pediatr Hematol Oncol,2014,31(6):518-527. [13] MAHUAD C V, REPARAZ M D E L, ZERGA M E, et al. Three years sustained complete remission achieved in a primary refractory ALK-positive anaplastic T large cell lymphoma treated with crizotinib[J]. Rare Tumors, 2016,8(2):6266. [14] SULLIVAN I, PLANCHARD D. ALK inhibitors in non-small cell lung cancer: the latest evidence and developments[J].Ther Adv Med Oncol, 2016,8(1):32-47. [15] CLEARY J M, RODIG S, BARR P M, et al. Crizotinib as salvage and maintenance with allogeneic stem cell transplantation for refractory anaplastic large cell lymphoma[J]. J Natl Compr Canc Netw,2014,12(3):323-326;quiz326. [16] MOSSÉ Y P,LIM M S,VOSS S D,et al.Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a children’s Oncology Group phase 1 consortium study[J].Lancet Oncol,2013,14(6): 472-480. [17] 杨菁,张永红,段彦龙.儿童间变性大细胞淋巴瘤31例误诊分析[J].实用儿科临床杂志,2008,23(15):1176-1178. [18] 杨景柯,朱兴虎,左文丽,等.间变性大细胞淋巴瘤(ALK阳性)误诊为横纹肌肉瘤1例并文献复习[J].中国医药导报,2013,10(3):109-111. |